The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia – experience of a secondary-level hospital
Medicinski glasnik
E-mail
sladjanapj@gmail.com
Ustanova
Department for Infectious Disease, General Hospital, Uzice, Republic of Serbia
Intensive care unit, General Hospital Uzice, Uzice, Republic of Serbia
Center for Neclear Medicine, University Clinical Center of Serbia, Belgrade, Republic of Serbia
Center for Radiology, University Clinical Center of Serbia, Belgrade, Republic of Serbia
Reference
Raban AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparativeoverview. Infez. Med. 2020; 28 (2): 174-84.
Van den Eynde E, Gasch O, Oliva JC, et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis. 2021; 53: 291-302. DOI: 10.1080/23744235.2021.1884286.
Bahrini K, Stambouli N, Ben Azaiez M, et al. Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit. J Immunol Res. 2023; 2023: 4059484. DOI: 10.1155/2023/4059484.
Sažetak
The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia – experience
of a secondary-level hospital
| Attachment | Size |
|---|---|
| 03 - 49-59 Medicinski glasnik 100 + References.pdf (273.67 KB) | 273.67 KB |